Bull & Bear

Bull and Bear

Verdict: Lean Long, Wait For Confirmation. The cycle thesis has empirical support in Q1 FY2026 and valuation is at a 20-year trough, but management credibility is depleted, the CEO and CFO are personally named in a federal class action, and segment-level Medicaid MCR is still moving the wrong way. Both sides agree the decisive line item is prior-year reserve development in Q1 and Q2 FY2026. The bull case rests on price (0.11x EV/Sales, ~8x normalized EPS) and the mechanical 12-24 month rate-cycle reset; the bear case rests on the 10-K's risk-factor migration and the covenant-relief amendment that says coverage was at risk. A setup, not yet a buy — own it intellectually now, size it only once the Q2 FY2026 reserve table confirms the inflection.

Bull Case

Bull scenario fair value & triggers. Bull-scenario fair value ~$265 over an 18-month window (June 2026 → December 2027), via 12x normalized FY2027-28 adj EPS of $22 — cross-checked at 0.28x EV/Sales on ~$47B FY27 premium (still a 50% discount to ELV's 0.55x). Validating signal: a consolidated MCR print at or below 89.5% in any quarter of FY2026 or H1 FY2027. Disconfirming signal: unfavorable prior-year reserve development in the Q1 or Q2 FY2026 medical claims and benefits payable rollforward — that line, not the headline EPS, would confirm the structural rate-inadequacy bear case.

Bear Case

Bear scenario downside & triggers. Bear-scenario downside ~$120 (~40% below the June 12, 2026 close of $200.28) over a 12-18 month window, via forward P/E re-rate on impaired earnings: at the $5 FY26 guide, a stressed-MCO trough multiple of ~20-25x implies $100-125; a P/B floor near 2.2x current $35 tangible book provides ~$80. Confirming signal: unfavorable PYD in the Q1 or Q2 FY2026 rollforward combined with Medicaid MCR sustained above 91% through Q3 FY2026 — the same line the bull names as disconfirming. Cover signal: consolidated MCR below 89% for two consecutive quarters with favorable PYD of at least $300M annualized, and OCF above 0.8x net income on a trailing four-quarter basis.

The Real Debate

Verdict

Lean Long, Wait For Confirmation. The bull side carries more weight on the durable thesis variable — 20-year-low valuation against a regulated rate-cycle whose 12-24 month reset cadence is visible in the Q1 OCF reversal, with a cost structure that survived a shock that broke Centene. The bear side wins the credibility layer convincingly enough to defer sizing: the 10-K's lead risk factor openly questions rate adequacy, the interest-coverage covenant was relieved in Feb 2026, PYD collapsed to $98M, and the CEO and CFO are personally named in an active federal securities class action — a combination that can pin the multiple even if MCR mean-reverts on schedule. Both sides have named the same Q1/Q2 FY2026 PYD line as decisive, and it will resolve before the durable cycle story does. The verdict shifts to Long on favorable PYD of at least $200M in the Q1 or Q2 FY2026 10-Q rollforward; it shifts to Avoid if that line comes back unfavorable in either quarter. Durable thesis breakers: sustained Medicaid-segment MCR above 91%, or a California Medi-Cal 2027 RFP loss.